Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CRSP

CRISPR Therapeutics AG

Sep 12 • 04:00PM ET

56.26

+0.37 0.66 %

Healthcare • Biotechnology • Switzerland • NASD

Peers: EDIT NTLA BEAM SGMO VRTX GILD BLUE ALLO CLLS ADPT

| Held by: ARKK IWM ARKG XBI VXF IWN IBB SCHA VTWO XT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.42	Insider Own	5.33%	Shs Outstand	88.38M	Perf Week	2.55%
Market Cap	5.12B	Forward P/E	-	EPS next Y	-4.01	Insider Trans	25.08%	Shs Float	86.10M	Perf Month	-1.87%
Enterprise Value	3.61B	PEG	-	EPS next Q	-1.24	Inst Own	77.11%	Short Float	25.64%	Perf Quarter	36.29%
Income	-467.80M	P/S	134.48	EPS this Y	-42.98%	Inst Trans	13.96%	Short Ratio	7.00	Perf Half Y	33.98%
Sales	38.05M	P/B	2.91	EPS next Y	35.31%	ROA	-21.41%	Short Interest	22.07M	Perf YTD	42.94%
Book/sh	19.36	P/C	2.97	EPS next 5Y	9.62%	ROE	-25.34%	52W High	71.13 -20.91%	Perf Year	23.40%
Cash/sh	18.96	P/FCF	-	EPS past 3/5Y	- -	ROIC	-24.51%	52W Low	30.04 87.28%	Perf 3Y	-10.36%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-65.58% -33.62%	Gross Margin	-249.00%	Volatility	4.48% 4.17%	Perf 5Y	-34.34%
Dividend TTM	-	EV/Sales	94.81	EPS Y/Y TTM	-69.19%	Oper. Margin	-1198.98%	ATR (14)	2.52	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	16.61	Sales Y/Y TTM	-81.18%	Profit Margin	-1229.43%	RSI (14)	54.66	Recom	1.94
Dividend Gr. 3/5Y	- -	Current Ratio	16.61	EPS Q/Q	-60.91%	SMA20	3.79%	Beta	1.80	Target Price	78.68
Payout	-	Debt/Eq	0.13	Sales Q/Q	72.53%	SMA50	-0.82%	Rel Volume	0.63	Prev Close	55.89
Employees	393	LT Debt/Eq	0.12	Earnings	Aug 04 AMC	SMA200	23.98%	Avg Volume	3.15M	Price	56.26
IPO	Oct 19, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-71.25% -85.47%	Trades		Volume	2,000,727	Change	0.66%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-25	Upgrade	Evercore ISI	In-line → Outperform	$60 → $99
Feb-12-25	Upgrade	TD Cowen	Sell → Hold	$35
Feb-03-25	Initiated	H.C. Wainwright	Buy	$65
Aug-06-24	Reiterated	Needham	Buy	$88 → $84
Aug-02-24	Initiated	Rodman & Renshaw	Buy	$90
Jun-28-24	Resumed	Guggenheim	Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-11-23	Downgrade	TD Cowen	Market Perform → Underperform	$30
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-27-23	Initiated	Mizuho	Buy	$82
Aug-17-23	Upgrade	Citigroup	Neutral → Buy
May-30-23	Initiated	William Blair	Outperform	$75
Apr-13-23	Initiated	Cantor Fitzgerald	Overweight	$72
Mar-21-23	Initiated	Bernstein	Mkt Perform	$44
Mar-17-23	Initiated	Bryan Garnier	Buy	$70
Mar-07-23	Initiated	Robert W. Baird	Neutral	$46
Oct-11-22	Initiated	Morgan Stanley	Underweight	$37
Aug-09-22	Downgrade	Barclays	Overweight → Equal Weight	$99 → $88
Jun-23-22	Downgrade	Evercore ISI	Outperform → In-line	$66 → $60
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$98

Show Previous Ratings

Sep-12-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Sep-11-25 11:14AM	CRISPR Therapeutics AG (CRSP)'s Casgevy Expands Global Adoption in 2025 (Insider Monkey) +7.87%
09:30AM	Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest? (Zacks)
03:45AM	Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190% (Motley Fool)
Sep-10-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
04:00PM	Loading…
Sep-09-25 04:00PM	CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025 (GlobeNewswire)
02:22PM	Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade. (Barrons.com)
Sep-03-25 11:30AM	CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound? (Zacks)
Sep-02-25 08:00AM	CRISPR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-01-25 09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Aug-31-25 08:40AM	Large-cap biotech is a sector to watch for investors: Analysts (Yahoo Finance)
Aug-29-25 04:21PM	1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) (Motley Fool)
10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
Aug-28-25 08:48AM	CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now? (Zacks)
Aug-25-25 12:21AM	H.C. Wainwright Lifts CRISPR Therapeutics' (CRSP) Price Target on CASGEVy Sales Growth (Insider Monkey)
11:15AM	Loading…
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
Aug-19-25 09:00AM	Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know (Zacks) -5.96%
Aug-18-25 09:03AM	What Makes Crispr Therapeutics Ag (CRSP) a Good Buy? (Insider Monkey)
Aug-17-25 11:41AM	Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns (Motley Fool)
Aug-13-25 07:30AM	[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Aug-12-25 11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)
Aug-08-25 09:00AM	Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock (Zacks)
Aug-06-25 03:24PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
Aug-05-25 11:54AM	CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption (Zacks) -6.71%
11:33AM	VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal (Zacks)
07:15AM	Up 50% in 3 Months, Is This Stock Still a Buy? (Motley Fool)
Aug-04-25 05:55PM	CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.24%
04:15PM	CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-01-25 05:11AM	New Strong Sell Stocks for August 1st (Zacks)
Jul-31-25 05:50PM	CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
09:44AM	Loading…
Jul-30-25 09:44AM	3 Genomics Stocks Worth Adding to Your Portfolio in 2025 (Zacks)
09:30AM	Should You Invest in CRISPR Therapeutics (CRSP) Based on Bullish Wall Street Views? (Zacks)
Jul-29-25 10:00AM	Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know (Zacks) -7.42%
09:14AM	Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards? (Zacks)
06:43AM	New Strong Sell Stocks for July 29th (Zacks)
06:00AM	The 3 Things That Matter for CRISPR Therapeutics Now (Motley Fool)
01:28AM	Jim Cramer Says "CRISPR Can Either Triple or Do Nothing" (Insider Monkey)
Jul-28-25 10:36AM	CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards? (Zacks)
10:00AM	CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-25-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Jul-24-25 06:00PM	CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
03:30PM	[Latest] Global CRISPR Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Jul-22-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Jul-21-25 12:07AM	3 Monster Stocks in the Making to Buy Right Now (Motley Fool)
Jul-19-25 02:16PM	CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading (Insider Monkey)
Jul-18-25 12:41PM	Crypto pops on GENIUS Act, Chinese tech stocks, CRISPR (Yahoo Finance Video) +18.22%
Jul-17-25 05:51AM	3 Monster Stocks to Hold for the Next 10 Years (Motley Fool)
Jul-15-25 06:00PM	CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors (Zacks) -6.54%
Jul-14-25 09:30AM	Is It Worth Investing in CRISPR Therapeutics (CRSP) Based on Wall Street's Bullish Views? (Zacks)
Jul-11-25 09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jul-10-25 08:53AM	CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally (Insider Monkey)
Jul-09-25 07:06PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research) +9.60%
10:45AM	Innovation ETF (ARKK) Hits New 52-Week High (Zacks)
08:30AM	Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers (PR Newswire)
Jul-07-25 06:00PM	Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market (Zacks) +7.09%
09:46AM	Intellia Gains 29.8% in a Month: How Should You Play the Stock? (Zacks)
Jul-03-25 09:18AM	H.C. Wainwright Reaffirms Buy Rating on CRISPR Therapeutics After CTX310 Update (Insider Monkey)
07:00AM	2 Beaten-Down Stocks With Massive Upside Potential (Motley Fool)
Jul-02-25 04:01AM	2 Growth Stocks to Buy Hand Over Fist in July (Motley Fool) +6.51%
Jul-01-25 04:01PM	Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer (GlobeNewswire)
Jun-30-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:30AM	Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock? (Zacks)
08:00AM	CRISPR Therapeutics Named to TIME's Most Influential Companies List of 2025 (GlobeNewswire)
Jun-27-25 09:30AM	Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
Jun-26-25 07:00AM	CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline (GlobeNewswire)
Jun-25-25 05:50PM	CRISPR Therapeutics AG (CRSP) Stock Moves 1.88%: What You Should Know (Zacks)
10:03AM	CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? (Zacks)
Jun-24-25 06:00PM	CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
04:06PM	CRISPR Therapeutics AG (CRSP): A Bull Case Theory (Insider Monkey)
04:17AM	The Best Stocks to Invest $1,000 in Right Now (Motley Fool)
Jun-21-25 06:10PM	2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts (Motley Fool)
Jun-20-25 04:08PM	The FDA Shake-Up Continues, And Could Impact Genetic Medicines (Investor's Business Daily)
Jun-19-25 07:22AM	Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? (Zacks)
Jun-18-25 05:50PM	CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
09:35AM	Gene-Editing Stocks Gain on LLY-VERV Deal Announcement (Zacks)
09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Jun-17-25 04:06PM	Verve Therapeutics Skyrockets Pulling Gene-Editing Stocks Higher On $1.3 Billion Eli Lilly Takeover (Investor's Business Daily)
Jun-11-25 10:33AM	CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? (Zacks)
Jun-10-25 05:50PM	CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts (Zacks)
Jun-06-25 09:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research) +8.53%
09:00AM	Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know (Zacks)
Jun-05-25 07:27PM	Analyst Report: CRISPR Therapeutics AG (Morningstar Research)
11:30AM	CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 10:58AM	BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy (Zacks)
08:55AM	Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? (Zacks)
Jun-03-25 04:30AM	The Best Stocks to Invest $1,000 in Right Now (Motley Fool)
Jun-02-25 07:45AM	The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip (Motley Fool)
May-29-25 08:30AM	CRISPR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-26-25 09:00AM	CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know (Zacks)
May-21-25 12:25PM	Crispr Therapeutics call volume above normal and directionally bullish (TipRanks) -5.76%
09:05AM	3 Top Genomics Stocks to Add to Your Portfolio in 2025 (Zacks)
May-20-25 11:30PM	CRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot Drug (Insider Monkey)
11:50AM	CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies (Zacks)
04:30AM	5 Monster Stocks to Hold for the Next 10 Years (Motley Fool)
03:43AM	CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy? (Motley Fool)
May-19-25 04:15PM	CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies (GlobeNewswire)
May-18-25 09:30AM	Prediction: This Beaten-Down Stock Could Double in The Next 5 Years (Motley Fool)
May-16-25 07:15AM	CRSPR Stock Could Be Ready to Deliver on Its Massive Promise (MarketBeat) +6.77%
May-14-25 07:45AM	Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics? (Motley Fool)
May-13-25 09:00AM	CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kulkarni Samarth	Chief Executive Officer	Aug 18 '25	Sale	58.15	13,081	760,660	207,004	Aug 19 04:30 PM
Treco Douglas A	Director	Aug 06 '25	Buy	57.03	20,000	1,140,600	22,000	Aug 08 04:06 PM
George Simeon	Director	Jul 16 '25	Buy	52.03	989,812	51,499,918	1,730,179	Jul 17 05:19 PM
Patel Naimish	Chief Medical Officer	May 29 '25	Sale	35.94	3,932	141,316	6,068	May 30 05:00 PM
Kulkarni Samarth	Chief Executive Officer	Mar 21 '25	Sale	41.23	10,031	413,578	195,085	Mar 24 05:35 PM
Bruno Julianne	Chief Operating Officer	Mar 21 '25	Sale	41.23	1,714	70,668	10,544	Mar 24 05:35 PM
Prasad Raju	Chief Financial Officer	Mar 21 '25	Sale	41.23	2,197	90,582	16,767	Mar 24 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 21 '25	Sale	41.23	3,185	131,318	81,729	Mar 24 05:35 PM
Prasad Raju	Chief Financial Officer	Mar 17 '25	Sale	41.80	3,762	157,252	12,714	Mar 18 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Mar 11 '25	Sale	42.42	9,973	423,055	180,890	Mar 12 07:05 PM
Kulkarni Samarth	Chief Executive Officer	Mar 12 '25	Sale	43.32	4,462	193,294	185,428	Mar 12 07:05 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 11 '25	Sale	42.42	2,850	120,897	77,530	Mar 12 07:05 PM
KASINGER JAMES R.	General Counsel and Secretary	Mar 12 '25	Sale	43.32	1,116	48,345	78,664	Mar 12 07:05 PM
Bruno Julianne	Chief Operating Officer	Mar 11 '25	Sale	42.42	1,198	50,819	8,263	Mar 12 07:05 PM
Bruno Julianne	Chief Operating Officer	Mar 12 '25	Sale	43.32	190	8,231	8,508	Mar 12 07:05 PM
Greene John	Director	Feb 26 '25	Buy	44.85	7,000	313,948	7,000	Feb 28 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 19 '25	Sale	55.20	18,360	1,013,564	171,613	Feb 21 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 18 '25	Sale	55.05	11,640	640,782	196,901	Feb 19 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Feb 19 '25	Sale	52.80	6,928	365,798	189,973	Feb 19 05:35 PM
Bruno Julianne	Chief Operating Officer	Feb 19 '25	Sale	52.80	333	17,582	7,062	Feb 19 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Feb 18 '25	Sale	53.85	9,595	516,691	73,002	Feb 19 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Feb 19 '25	Sale	52.80	1,947	102,802	74,880	Feb 19 05:35 PM
Samarth Kulkarni	Officer	Feb 18 '25	Proposed Sale	52.22	45,000	2,349,900		Feb 18 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Dec 24 '24	Option Exercise	16.21	13,751	222,904	195,291	Dec 27 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Dec 02 '24	Sale	55.10	15,000	826,564	181,540	Dec 04 05:35 PM
Kulkarni Samarth	Chief Executive Officer	Nov 11 '24	Sale	55.62	30,000	1,668,678	196,540	Nov 13 05:35 PM
KASINGER JAMES R.	General Counsel and Secretary	Oct 14 '24	Sale	46.28	1,089	50,399	62,597	Oct 15 06:00 PM
Kulkarni Samarth	Chief Executive Officer	Oct 14 '24	Sale	46.28	4,293	198,680	226,540	Oct 15 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRSP

CRISPR Therapeutics AG

Upgrade your FINVIZ experience